Floating medtechs go big or go home
IPOs in the medical device sector are bigger than in biotech, but performance, at least of the biggest groups, is mixed.
Spac listings slow as the hunt for deals continues
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Biotech listings shows few signs of cooling
IPOs of drug developers raised $9bn in the first half of 2021, a record amount that is hard to square with talk of moderation.
The next wave of amyloid-targeting projects approaches
Acumen is the latest player to take aim at amyloid, but competition is fierce.
Europe’s venture boom trails the US
But financing sizes have grown by a similar amount on both sides of the Atlantic.
Roivant rewrites the Spac script, again
After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.
